Company
Avicanna Inc
TSE:AVCN
Avicanna Inc is an international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid products for the global medical and pharmaceutical market segments. The company has an established scientific platform including R&D and clinical development which lead to the commercialization of more than thirty products globally. Medical Cannabis & Wellness Products: RHO Phyto is a full formulary of products including oral, sublingual, topical, and transdermal deliveries with controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. Pharmaceutical Pipeline: Leveraging its scientific platform, vertical integration, and real-world evidence, Avicanna has created a pipeline of patent-pending drug candidates that are indication-specific and in various stages of clinical development and commercialization.
33 stories · page 2 of 2
Avicanna posts 42% Q3 revenue growth
“During the third quarter, we successfully completed a complex technical and regulatory transfer of a sizable portion of our Canadian products, which we deemed necessary for scale-up and improvement of margins in the long term,” said CEO Ar
Avicanna closes private placement to boost production and manufacturing capacity, research and development
The company issued 1,790,750 units at a price of $0.35 per unit for aggregate gross proceeds of around $626,762.50
Avicanna patents novel cannabinoid formulation for reducing seizures and sudden unexpected death in epilepsy
The formulation candidate showed anti-convulsant properties and strong potential to treat patients diagnosed with intractable forms of epilepsies and those at risk of seizure-induced sudden unexpected death in epilepsy, Avicanna said
Avicanna launches medical cannabis education portal Avicenna Academy for health care professionals
"We are excited about the launch of this platform as a resource that facilitates information and education to potentially improve patient outcomes and foster further collaboration with the medical community," said Avicanna CEO Aras Azadian
Avicanna collaborates with University of Toronto to expand its epilepsy research program
The commercial-stage biopharmaceutical company said Dr Mac Burnham’s team will explore efficacy of Avicanna’s drug candidates and its proprietary combination of cannabinoids in a pre-clinical model for seizures
Avicanna is innovating and commercializing industry-leading cannabinoid-based wellness, medical and pharmaceutical products
Toronto-based biopharmaceutical company Avicanna Inc is looking to disrupt industries such as dermatology, oncology, and neurology with its cannabinoid products
Avicanna closes strategic non-brokered private placement offering of units for aggregate gross proceeds of approximately $2.782M
The company said it intends to use the proceeds from the offering for general working capital purposes, general and administrative expenses, expenditures related to production and manufacturing, research and clinical development
Avicanna highlights 101% year-on-year increase in revenue for the six months to June 30, 2022
"We are pleased to report on our continued progress and global commercialization efforts where we primarily focused on, and achieved, growth of our four brands in the Canadian marketplace," said Aras Azadian, CEO at Avicanna
Avicanna enters agreement with Ei.Ventures to develop and commercialize functional fungi-based products
"Over the past six years our team established a scientific platform that has led to the commercialization of several products across international commercial channels in the regulated cannabis industry,” said Avicanna CEO Aras Azadian